Study of POMELLA™ Extract to Treat Prostate Cancer

Inclusion Criteria: * Men 18 years or older (19 years in BC) with a histologic diagnosis of clinically localized prostate cancer prior to radical prostatectomy as defined by: 1. Clinical state T1-T2 2. PSA \<20 3. Gleason score ≤ 7 * ECOG performance status of 0-1. * Life expectancy greater than 10 years. * Able to understand and give informed consent. * Laboratory values must be as follows: 1. White blood cell count: ≥ 3,000/mm\^3 2. Absolute granulocyte count: ≥ 1,500/mm\^3 3. Platelets: ≥ 100,000/mm\^3 4. Hemoglobin: ≥ 12g/dL 5. Serum creatinine: ≤ 1.5 x ULN 6. AST: ≤ 2 x ULN 7. ALT: ≤ 2 x ULN 8. Serum calcium: ≤ ULN 9. Total bilirubin: ≤ 1.5 x ULN Exclusion Criteria: * Patients who are receiving any other investigational therapy. * Patients who have received or are receiving any other treatment for their prostate cancer. * Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment. * Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent. * Histologic evidence of small cell carcinoma of the prostate. * Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible for study. * Patients who are receiving any androgens, estrogens or progestational agents. * Patients with a known hypersensitivity to pomegranates or composites of the capsules/placebo: hydroxypropyl methylcellulose, silicon dioxide or aerosol. * Patients who are taking any drugs or natural health products which might impact biochemical tests (some examples include: spironolactone, aprepitant, bexarotene, clarithromycin, itraconazole, ketoconazole, St. John's wort). A washout period of 30 days prior to commencing the study would be necessary for these compounds if required. * Patients who have chronic active hepatitis. * Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained.